Drug intelligence / Profile preview

DN-022150

Development stage: Phase 3
Lead developer: Jiangxi Kerui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

DN-022150 is a small molecule inhibitor targeting the KRAS G12D mutation, developed by Jiangxi Kvvit Pharmaceutical (also known as Qingfeng Pharmaceutical Group). KRAS G12D is a prevalent oncogenic driver in various cancers, particularly pancreatic, colorectal, and non-small cell lung cancers. By selectively inhibiting the mutant KRAS protein, DN-022150 aims to disrupt the constitutive activation of downstream signaling pathways responsible for uncontrolled cellular proliferation and survival. The drug is currently undergoing Phase I/IIa clinical evaluation in China to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors harboring the KRAS G12D mutation.

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on DN-022150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN-022150.

Explore the full profile